Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, October 27, 2005 3:29:52 PM
Predix president and CEO Dr. Michael Kauffman: We’ll continue our clinical trials for our three flagship products.
Tali Tsipori 27 Oct 05 19:34
Only a few weeks after initial reports that drug developer Predix Pharmaceuticals Ltd. would cancel its planned IPO on Nasdaq, the company officially announced that its withdrawal. As “Globes” first reported, Predix said it was cancelling the IPO, due to what it termed “market conditions”.
Demand for Predix’s share was reportedly less than half the $55 million that the company had hoped to raise at a company value of just over $200 million.
Predix’s future operations will now be based mainly on the proceeds from private placements or public financing rounds.
Despite an uncertain future, Predix president and CEO Dr. Michael Kauffman is optimistic. “Although we decided to withdraw the IPO for now, we’ll continue our clinical trials for our three flagship products,” he said.
Published by Globes [online], Israel business news - www.globes.co.il - on October 27, 2005
Dubi
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM